GlassScriptPhysician profile
Lindsay M Snow
NPI 1134579030
$2,480.28
in general payments reported to CMS, 2019-2025
20 companies · $828 in 2025
The $828 reported for 2025 was more than what 83% of Family Medicine providers received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2023: $503 · 2024: $1,149 · 2025: $828.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,480.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,480.28 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $634.36 | 2023-2025 | Qulipta, Ubrelvy, Synthroid |
| Novo Nordisk INC | $331.08 | 2023-2025 | Rybelsus, Ozempic, Wegovy |
| Glaxosmithkline, LLC. | $268.73 | 2023-2025 | Arexvy, Trelegy Ellipta, Shingrix |
| Lilly USA, LLC | $265.71 | 2023-2025 | Mounjaro, Jardiance, Zepbound |
| Astrazeneca Pharmaceuticals LP | $213.90 | 2024-2025 | Airsupra, Farxiga, Breztri |
| Amgen INC. | $149.74 | 2023-2025 | Otezla, Repatha, Otezla |
| Abiomed | $146.18 | 2023 | Impella |
| Exact Sciences Corporation | $115.36 | 2023-2025 | Cologuard Collection Kit |
| Pfizer INC. | $75.29 | 2024-2025 | |
| Bausch Health US, LLC | $40.11 | 2025 | Wellbutrin, Aplenzin |
| Boehringer Ingelheim Pharmaceuticals, INC. | $34.50 | 2023-2024 | Jardiance |
| Kowa Pharmaceuticals America, INC. | $33.31 | 2025 | Zoryve |
| Vanda Pharmaceuticals INC. | $33.24 | 2025 | Fanapt, Hetlioz |
| Astellas Pharma US INC | $32.14 | 2024 | Veozah |
| Phathom Pharmaceuticals, INC. | $30.08 | 2024 | Voquezna |
Show all 20 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Iti, INC. (D/B/A Intra-Cellular Therapies, INC.) | $17.46 | 2024 | Caplyta |
| Novartis Pharmaceuticals Corporation | $16.87 | 2023 | |
| Idorsia Pharmaceuticals US INC | $15.22 | 2024 | Quviviq |
| Acella Pharmaceuticals, LLC | $14.19 | 2024 | NP Thyroid 60 |
| Bayer Healthcare Pharmaceuticals INC. | $12.81 | 2023 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Lindsay Snow listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.